<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22239" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Giant Cell Tumor (Osteoclastoma)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hosseinzadeh</surname>
            <given-names>Shayan</given-names>
          </name>
          <aff>Boston Children's Hospital, Harvard Medical School</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tiwari</surname>
            <given-names>Vivek</given-names>
          </name>
          <aff>Apollo Sage Hospital, Bhopal, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Jesus</surname>
            <given-names>Orlando</given-names>
          </name>
          <aff>University of Puerto Rico, Medical Sciences Campus, Neurosurgery Section</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shayan Hosseinzadeh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vivek Tiwari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Orlando De Jesus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22239.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Giant cell tumor (GCT) is one of the most common benign bone tumors,&#x000a0;predominantly occurring in young adults aged 20 to 40 with a high recurrence rate and&#x000a0;the potential for aggressive behavior. Typically found at the&#x000a0;metaphyseal or epiphyseal&#x000a0;regions of the tibia or femur, GCT, despite its predominantly benign nature, exhibits a highly unpredictable spectrum of disease behavior. Local aggressiveness varies from focal symptoms&#x000a0;arising&#x000a0;from bony or cortical destruction and surrounding soft tissue expansion to the rare occurrence of metastasis.</p>
        <p>This activity discusses the&#x000a0;critical aspects, including the typical age range of affected individuals (20 to 40 years), common anatomical locations (metaphysis or epiphysis of the femur or tibia), and the inherent challenges associated with its recurrence and potential for aggressive behavior. The spectrum of disease behavior, ranging from local aggressiveness to occasional metastasis, especially in unresectable cases in the axial skeleton, is highlighted.&#x000a0;This course is designed to equip clinicians&#x000a0;with effective management strategies for patients. This&#x000a0;activity is a valuable resource for clinicians seeking a deeper understanding of GCT, enabling them to provide informed and optimal care to individuals affected by this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between giant cell tumor and other bone lesions through a comprehensive analysis of histological and imaging findings.</p></list-item><list-item><p>Implement evidence-based diagnostic and therapeutic interventions for&#x000a0;giant cell tumor, considering the tumor's location and potential for recurrence.</p></list-item><list-item><p>Apply updated knowledge of molecular markers, such as H3F3A mutations, to enhance diagnostic accuracy and guide treatment decisions.</p></list-item><list-item><p>Collaborate with an interprofessional team, including orthopedic surgeons, radiologists, and pathologists, to ensure comprehensive and coordinated care for&#x000a0;giant cell tumor patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22239&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22239">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22239.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Giant cell tumor (GCT) is one of the most common benign bone tumors,&#x000a0;predominantly occurring in young adults aged 20 to 40 with a high recurrence rate and&#x000a0;the potential for aggressive behavior.<xref ref-type="bibr" rid="article-22239.r1">[1]</xref>&#x000a0;Typically found at the&#x000a0;metaphyseal or epiphyseal&#x000a0;regions of the tibia or femur, GCT, despite its predominantly benign nature, exhibits a highly unpredictable spectrum of disease behavior. Local aggressiveness varies from focal symptoms&#x000a0;arising&#x000a0;from bony or cortical destruction and surrounding soft tissue expansion to the rare occurrence of metastasis. Instances of GCT within the axial skeleton pose a heightened risk of&#x000a0;severe local complications and are often deemed&#x000a0;unresectable.<xref ref-type="bibr" rid="article-22239.r2">[2]</xref></p>
        <p>Under the microscope, the biopsied tissue reveals multinucleated giant cells comprising 3 distinct cell types:&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Giant cell tumor stromal cells&#x000a0;originating from osteoblasts</p>
          </list-item>
          <list-item>
            <p>Mononuclear histiocytic cells</p>
          </list-item>
          <list-item>
            <p>Multinucleated giant cells&#x000a0;belonging to&#x000a0;an osteoclast-monocyte lineage&#x000a0;<xref ref-type="bibr" rid="article-22239.r3">[3]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>The giant cells carry out the primary task of tumor bone resorption within the tumor. The spindle-like stromal cells are pivotal&#x000a0;in recruiting monocytes and&#x000a0;facilitating their fusion into giant cells. The stromal cells also improve the resorptive&#x000a0;capabilities&#x000a0;of the giant cells, contributing to the overall bone resorption mechanism.</p>
      </sec>
      <sec id="article-22239.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The&#x000a0;precise etiology of GCT is not fully understood, and there is ongoing debate about whether it represents a true neoplasm or a reactive condition. Notably, a 20q11 amplification is seen in 54% of GCTs, and 20% of cases exhibit over-expression of p53. Centrosome amplification and boosted telomerase activity, coupled with the prevention of telomere shortening, provide evidence supporting a neoplastic origin.<xref ref-type="bibr" rid="article-22239.r4">[4]</xref><xref ref-type="bibr" rid="article-22239.r5">[5]</xref><xref ref-type="bibr" rid="article-22239.r6">[6]</xref></p>
      </sec>
      <sec id="article-22239.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>GCTs represent&#x000a0;4% to 10% of all primary bone tumors and 15% to 20% of benign bone tumors&#x000a0;<xref ref-type="bibr" rid="article-22239.r7">[7]</xref>,&#x000a0;with a preference for affecting&#x000a0;young adults. Approximately half of these tumors occur in&#x000a0;individuals&#x000a0;during their&#x000a0;third and fourth decades of life, with rarity observed in those older than 50. There is a female-to-male ratio between 1.3&#x000a0;and 1.5&#x000a0;to 1, and the incidence is higher among&#x000a0;Asian populations than in&#x000a0;Western populations. Among the reported cases,&#x000a0;44%&#x000a0;are situated around the&#x000a0;knee joint, 10% in the distal radius, 6% in the proximal humerus, and 13% in the hands and feet.<xref ref-type="bibr" rid="article-22239.r7">[7]</xref> The spine and skull are rarely affected. In the axial skeleton, the ala of the sacrum is the most common location, and when the spine is involved, the vertebral body is the most commonly affected. The mandible and maxilla are&#x000a0;preferred&#x000a0;in the head, while in the hand, GCTs frequently occur in the phalanges.</p>
        <p>Although benign, GCTs exhibit locally aggressive behavior and&#x000a0;have the potential to metastasize. Around 1% to 5% of cases show metastasis, with a notable positive correlation between the occurrence of metastases and local aggressiveness and recurrence.<xref ref-type="bibr" rid="article-22239.r8">[8]</xref>&#x000a0;The lungs are the most common site for metastases.<xref ref-type="bibr" rid="article-22239.r9">[9]</xref>&#x000a0;Varying degrees of local aggressiveness, ranging from simple cortical breakthrough to extension into surrounding soft tissues and articular structures, can cause severe and debilitating local complications. The risk of recurrence is approximately 35%.<xref ref-type="bibr" rid="article-22239.r10">[10]</xref></p>
        <p>The tumor&#x000a0;typically occurs sporadically before the age of 20, with less than 5% of cases presenting in skeletally immature&#x000a0;patients.<xref ref-type="bibr" rid="article-22239.r11">[11]</xref>&#x000a0;A higher&#x000a0;incidence of vertebral&#x000a0;GCT and multicentricity is noted&#x000a0;in patients with skeletal immaturity. Although less common, multifocal lesions exhibit more aggressiveness than solitary lesions.<xref ref-type="bibr" rid="article-22239.r12">[12]</xref>&#x000a0;In individuals with Paget disease, there is an elevated occurrence of GCT, with a preference for flat bones like&#x000a0;the skull&#x000a0;and pelvis.<xref ref-type="bibr" rid="article-22239.r13">[13]</xref></p>
      </sec>
      <sec id="article-22239.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of GCT appears to be significantly influenced by the receptor activator of the nuclear factor kappa B [NF-kB] ligand (RANKL). Under normal physiologic conditions, osteoclast formation requires interaction with cells of the osteoblastic lineage, which may depend upon cell-cell contact and the interaction of RANKL with its receptor RANK.<xref ref-type="bibr" rid="article-22239.r14">[14]</xref>&#x000a0;Monocytes express high levels of this receptor, while various cell types, including stromal cells and lymphocytes, express RANKL. Different coregulatory molecules also participate in osteoclast formation, including monocyte-colony-stimulating factor, vitamin D, parathyroid and parathyroid hormone-related protein, and prostaglandins.<xref ref-type="bibr" rid="article-22239.r15">[15]</xref></p>
        <p>Several studies identified a high expression of RANKL by stromal cells within GCTs.<xref ref-type="bibr" rid="article-22239.r15">[15]</xref><xref ref-type="bibr" rid="article-22239.r16">[16]</xref>&#x000a0;These stromal cells also secrete factors that can regulate or prevent osteoclastogenesis, including osteoprotegerin,&#x000a0;serving as a natural negative regulator of RANKLE that obstructs&#x000a0;osteoclast and osteoblast&#x000a0;interactions and functions as a natural negative regulator of RANKL.<xref ref-type="bibr" rid="article-22239.r17">[17]</xref>&#x000a0;The expression of RANKL by the osteoblast-like mononuclear stromal cells stimulates the recruitment of the osteoclastic cells from a normal monocytic pre-osteoclast cell. The osteoclastic giant cells then actively absorb host bone via a cathepsin K and matrix metalloproteinase 13-mediated process, which would account for the osteolysis associated with these tumors.<xref ref-type="bibr" rid="article-22239.r18">[18]</xref></p>
        <p>Mutations in the&#x000a0;H3F3A&#x000a0;gene,&#x000a0;found in over 90% of GCT,&#x000a0;are implicated in driving tumorigenesis. These mutations are restricted to the stromal cell population and are&#x000a0;absent in osteoclasts or their precursors.<xref ref-type="bibr" rid="article-22239.r19">[19]</xref>&#x000a0;Neoplastic stromal cells likely&#x000a0;possess an immature osteoblast phenotype,&#x000a0;expressing markers such as&#x000a0;RANKL and other&#x000a0;indicators of the early osteoblast lineage within their transcriptional repertoire.<xref ref-type="bibr" rid="article-22239.r20">[20]</xref>&#x000a0;The activation of stromal cells has been hypothesized to occur not from inherent genetic changes but rather from the local release of red cells and plasma proteins into the matrix induced by hemorrhage. Maintaining the stromal cells' immature state may involve unknown reciprocal signals from giant cells. RANKL has been identified as a primary molecular target for therapeutic interventions.<xref ref-type="bibr" rid="article-22239.r14">[14]</xref></p>
        <p>Furthermore, investigations into PD-L1 levels among patients with GCT have revealed higher local recurrence rates in individuals expressing PD-L1.<xref ref-type="bibr" rid="article-22239.r21">[21]</xref>&#x000a0;There is speculation that&#x000a0;PD-L1 immune checkpoint inhibitors may benefit patients&#x000a0;experiencing recurrent GCT&#x000a0;following denosumab therapy.<xref ref-type="bibr" rid="article-22239.r22">[22]</xref><xref ref-type="bibr" rid="article-22239.r23">[23]</xref></p>
      </sec>
      <sec id="article-22239.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Upon&#x000a0;gross inspection, these lesions&#x000a0;exhibit characteristic features such as chocolate brown, soft and spongy texture, and fragility.<xref ref-type="bibr" rid="article-22239.r24">[24]</xref>&#x000a0;Yellow-to-orange discoloration from the hemosiderin&#x000a0;can also be present. Commonly, cystic blood-filled cavities within the tumor may be observed.<xref ref-type="bibr" rid="article-22239.r1">[1]</xref>&#x000a0;Examination typically reveals a variable degree of cortical expansion and disruption while the periosteum remains intact.<xref ref-type="bibr" rid="article-22239.r25">[25]</xref>&#x000a0;</p>
        <p>Histologically, these lesions appear&#x000a0;cellular, featuring a distinctive composition of multinucleated giant cells and a&#x000a0;background network of mononuclear stromal cells.<xref ref-type="bibr" rid="article-22239.r20">[20]</xref>&#x000a0;The mononuclear cells&#x000a0;can exhibit a variety of shapes, including&#x000a0;plump, oval, or spindle-shaped, and may display prominent mitotic activity,&#x000a0;although cellular atypia is uncommon. The multinucleate giant cells have numerous centrally located nuclei, unlike the peripherally located nuclei of Langerhans-type giant cells observed&#x000a0;in atypical infections. The nuclei&#x000a0;of these giant cells are compact and oval, containing prominent nucleoli. Giant cells&#x000a0;are distributed throughout the lesion, and the concentration of multinucleated giant cells&#x000a0;can vary&#x000a0;from tumor to tumor.&#x000a0;While some tumors&#x000a0;feature numerous multinucleated giant cells,&#x000a0;others have limited giant cells settled in whirls of spindle-shaped stromal cells. In approximately 5% of cases, giant cells invade small perforating vessels.</p>
        <p>In benign bone GCTs, 3 distinct cell types are identified:<xref ref-type="bibr" rid="article-22239.r26">[26]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Type I cells: Resembling interstitial fibroblasts; these cells produce collagen and exhibit proliferative capabilities. This cell likely constitutes the tumor component of GCT and shares features&#x000a0;with mesenchymal stem cells.&#x000a0;Their&#x000a0;characteristics suggest a potential early&#x000a0;differentiation into osteoblasts.<xref ref-type="bibr" rid="article-22239.r27">[27]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Type II cells: Also interstitial, these cells resemble the monocyte/macrophage family and could potentially be recruited from the peripheral bloodstream.<xref ref-type="bibr" rid="article-22239.r1">[1]</xref>&#x000a0;Type II cells serve as precursors&#x000a0;to the multinucleated giant cells within the tumor.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Type III cells:&#x000a0;Represented by multinucleated giant cells, these cells share many characteristics&#x000a0;with osteoclasts and&#x000a0;display similar morphologies.<xref ref-type="bibr" rid="article-22239.r15">[15]</xref>&#x000a0;Type III cells possess&#x000a0;enzymes for bone resorption, including tartrate-resistant acid phosphatase and type II carbonic anhydrase.<xref ref-type="bibr" rid="article-22239.r28">[28]</xref><xref ref-type="bibr" rid="article-22239.r29">[29]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Type II and type III cells exhibit significant activity for insulin-like growth factors 1 and 2, while this activity is notably absent in type I cells. This observation implies that insulin-like growth factors 1 and&#x000a0;2 play a crucial role in the development and regulation of GCTs.<xref ref-type="bibr" rid="article-22239.r1">[1]</xref>&#x000a0;</p>
        <p>Genetically, 80% of individuals with&#x000a0;GCTs of the bone exhibit the cytogenetic abnormality of telomeric associations (tas),&#x000a0;with half of the cells in the tumor showing the tas abnormality.<xref ref-type="bibr" rid="article-22239.r30">[30]</xref>&#x000a0;The RANK pathway is often&#x000a0;implicated in the&#x000a0;pathogenesis of GCT, representing a crucial signaling pathway&#x000a0;in bone remodeling. This pathway plays a critical role in the differentiation of precursors into multinucleated osteoclasts and the activation of osteoclasts, leading to bone resorption.<xref ref-type="bibr" rid="article-22239.r31">[31]</xref>&#x000a0;H3F3A gene mutations are reported in around 69% to 100%&#x000a0;of GCTs. Recently, a case of&#x000a0;GCT of the bone was found to have an H3F3B gene mutation.<xref ref-type="bibr" rid="article-22239.r32">[32]</xref>&#x000a0;Yakoub et al reported&#x000a0;2 cases of giant cell-poor GCT of the bone, diagnosed by the presence of H3.3 G34W monoclonal antibody in the mononuclear cells&#x000a0;through immunohistochemistry.<xref ref-type="bibr" rid="article-22239.r33">[33]</xref></p>
      </sec>
      <sec id="article-22239.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The&#x000a0;presentation of GCTs can vary, and common findings include the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pain:</bold>&#x000a0;The most&#x000a0;prevalent&#x000a0;symptom, often due to mechanical insufficiency resulting from bone destruction.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Swelling and deformity:</bold>&#x000a0;Associated with more extensive lesions.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>A soft tissue mass or bump:</bold>&#x000a0;Occasional&#x000a0;and results from cortical destruction and tumor progression outside the bone, typically found close to the joint. A limited range of motion at the joint area is expected.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Joint effusion and synovitis:</bold>&#x000a0;Possible manifestations</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pathological fractures:&#x000a0;</bold>Approximately 12% of patients present with fractures at diagnosis.<xref ref-type="bibr" rid="article-22239.r34">[34]</xref><xref ref-type="bibr" rid="article-22239.r35">[35]</xref>&#x000a0;The pathologic fracture incidence at presentation is 11% to 37%, indicating a potentially more aggressive disease with a higher risk of local recurrence and metastatic spread.<xref ref-type="bibr" rid="article-22239.r29">[29]</xref><xref ref-type="bibr" rid="article-22239.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Epiphyseal location:</bold>&#x000a0;Found in 90% of tumors, often extending to the articular subchondral bone or abutting the cartilage. It rarely invades the joint or its capsule. In skeletally immature patients, lesions are likely found in the metaphysis.<xref ref-type="bibr" rid="article-22239.r37">[37]</xref><xref ref-type="bibr" rid="article-22239.r38">[38]</xref>&#x000a0;Only 1.2% of GCT involved metaphysis or diaphysis without epiphyseal involvement.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Common locations:</bold>&#x000a0;Descending order of occurrence includes the distal femur, proximal tibia, distal radius, and sacrum.<xref ref-type="bibr" rid="article-22239.r39">[39]</xref>&#x000a0;Half of all GCTs arise around the knee region. Other sites include the proximal femur, fibular head, and proximal humerus. Pelvic bone&#x000a0;involvement&#x000a0;is&#x000a0;relatively rare.<xref ref-type="bibr" rid="article-22239.r40">[40]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Multicentricity:</bold>&#x000a0;The simultaneous occurrence of GCT in different sites occurs but is exceedingly rare.<xref ref-type="bibr" rid="article-22239.r41">[41]</xref><xref ref-type="bibr" rid="article-22239.r42">[42]</xref>&#x000a0;Most commonly, GCT is a solitary lesion. Multicentric involvement (&#x0003c;1%) is clinically aggressive and&#x000a0;tends to affect&#x000a0;the small bones of the hands and feet,&#x000a0;showing differences from&#x000a0;solitary lesions. Patients with multicentric lesions are generally younger than those with lesions elsewhere.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22239.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The evaluation for GCT&#x000a0;involves a combination of laboratory and imaging studies, followed by a biopsy for a definitive diagnosis. Below is a detailed discussion.</p>
        <p>
<bold>Blood Investigations</bold>
</p>
        <p>Routine<bold>&#x000a0;</bold>blood investigations&#x000a0;are conducted as part of the&#x000a0;preoperative workup. Specifically, serum acid phosphatase should be&#x000a0;assessed, as it is known to be increased in patients with GCT and can correlate with treatment response.&#x000a0;This is especially useful in cases&#x000a0;of local recurrence. In a retrospective study, Hayashida et al reported that tartrate-resistant acid phosphatase 5b levels were found to be raised in younger patients and those with fewer pathological secondary changes. Interestingly, these levels do not necessarily correlate with tumor volume.<xref ref-type="bibr" rid="article-22239.r43">[43]</xref></p>
        <p>
<bold>Imaging&#x000a0;Modalities</bold>
</p>
        <p>Radiograph examination typically reveals a characteristic radiolucent geographic appearance with a narrow transition zone at the lesion margin (see <bold>Image.&#x000a0;</bold>Lytic Lesion).&#x000a0;Unlike many benign lesions, GCT lacks a prominent sclerotic rim at the lesion margin. Calcification of the matrix, periosteal reaction,&#x000a0;and new bone formation are typically absent.<xref ref-type="bibr" rid="article-22239.r20">[20]</xref>&#x000a0;The lesion is eccentrically located in the epiphyseal&#x000a0;portion and tends to extend up to a centimeter&#x000a0;into the subchondral bone.</p>
        <p>Imaging modalities such as&#x000a0;computed tomography (CT) scan and&#x000a0;magnetic resonance imaging (MRI) can confirm the typical subchondral location of&#x000a0;GCTs within the bone and assess the extent of a soft tissue mass, either beyond the bone cortex or&#x000a0;through the adjacent joint.<xref ref-type="bibr" rid="article-22239.r44">[44]</xref><xref ref-type="bibr" rid="article-22239.r45">[45]</xref>&#x000a0;Functional positron emission tomography (PET) and bone scans are other modern imaging modalities that can determine the extent of disease involvement.</p>
        <p>CT scans provide a more accurate assessment of cortical thinning, penetration, and bone mineralization&#x000a0;than plain radiographs. The neocortex formation and tumor density can be visualized, helping distinguish primary osteosarcoma. A chest CT scan&#x000a0;is recommended in patients with locally recurrent disease to assess for metastatic spread.&#x000a0;</p>
        <p>MRI&#x000a0;is a crucial tool&#x000a0;for assessing the integrity of the surrounding soft tissues, neurovascular structures, and the extent of subchondral extension into adjacent joints. GCT lesions typically present with homogeneous signal intensity,&#x000a0;appearing as&#x000a0;well-circumscribed&#x000a0;lesions on MRI.&#x000a0;On T1-weighted images, these lesions exhibit low signal intensity, while on T2-weighted images, intermediate signal intensity is observed. The typical features include an expansile hypervascular mass with cystic changes, displaying heterogeneous low to intermediate signal intensity on T1-weighted images and intermediate to high intensity on T2-weighted images.<xref ref-type="bibr" rid="article-22239.r24">[24]</xref><xref ref-type="bibr" rid="article-22239.r25">[25]</xref>&#x000a0;Notably, areas of low signal intensity on both T1 and T2-weighted images are attributed to the accumulation of significant amounts of hemosiderin.<xref ref-type="bibr" rid="article-22239.r20">[20]</xref>&#x000a0;MRI helps assess the soft tissue mass and cystic components&#x000a0;within&#x000a0;the tumor. For the evaluation of residual or recurrent GCT, fat-suppression fluid-sensitive sequences in MRI are useful.<xref ref-type="bibr" rid="article-22239.r23">[23]</xref></p>
        <p>Bone scans&#x000a0;aid in&#x000a0;staging multicentric disease, although findings, typically revealing a decrease in the radiotracer uptake in the tumor's center, lack specificity for GCTs. Aneurysmal bone cysts&#x000a0;exhibit a similar appearance. Limited data exist regarding fluorine-18 fluorodeoxyglucose (FDG)-PET for newly diagnosed GCT. GCT shows the accumulation of the FDG tracer,&#x000a0;distinguishing it from many benign bone tumors, presumably&#x000a0;due to&#x000a0;the active metabolism of osteoclast-like giant cells.<xref ref-type="bibr" rid="article-22239.r26">[26]</xref><xref ref-type="bibr" rid="article-22239.r27">[27]</xref>&#x000a0;However, the advantages of FDG PET evaluation compared to conventional imaging with CT, MRI, or a bone scan remain unclear.&#x000a0;Changes in FDG uptake over time correlate with the tumor's metabolism and angiogenic activity.<xref ref-type="bibr" rid="article-22239.r28">[28]</xref>&#x000a0;Additionally, the response to denosumab therapy can be assessed using 18F-fluorodeoxyglucose-positron avidity.<xref ref-type="bibr" rid="article-22239.r23">[23]</xref></p>
        <p>
<bold>Biopsy and Immunohistochemistry</bold>
</p>
        <p>Biopsy samples undergo immunohistochemistry, and identifying the H3.3-G34W mutation&#x000a0;is sensitive and specific&#x000a0;for diagnosing GCT, helping differentiate it from other giant cell-rich tumors.<xref ref-type="bibr" rid="article-22239.r46">[46]</xref><xref ref-type="bibr" rid="article-22239.r47">[47]</xref>&#x000a0;Furthermore, detecting this mutation provides valuable insights into the molecular characteristics of GCT, informing potential therapeutic approaches and prognostic considerations for patients.</p>
      </sec>
      <sec id="article-22239.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of&#x000a0;GCT involves a multidisciplinary approach, combining surgical, medical, and sometimes radiation therapies. The specific approach depends on factors such as the tumor's location, size, aggressiveness, and whether it is primary or recurrent.</p>
        <p>
<bold>Surgical Resection</bold>
</p>
        <p>The standard care for treating GCT often involves a tailored approach considering the benign nature of most GCTs, their proximity to joints in young adults, and the goal of preserving bone anatomy. Many&#x000a0;authors advocate for an intralesional approach&#x000a0;rather than resection to maintain bone integrity.<xref ref-type="bibr" rid="article-22239.r48">[48]</xref><xref ref-type="bibr" rid="article-22239.r49">[49]</xref><xref ref-type="bibr" rid="article-22239.r50">[50]</xref></p>
        <p>While wide resection has been associated with a decreased risk of local recurrence, potentially raising the recurrence-free survival rate from 84% to 100%,<xref ref-type="bibr" rid="article-22239.r29">[29]</xref><xref ref-type="bibr" rid="article-22239.r51">[51]</xref><xref ref-type="bibr" rid="article-22239.r52">[52]</xref>&#x000a0;this approach comes with higher rates of surgical complications. It may lead to functional impairment, necessitating reconstruction.<xref ref-type="bibr" rid="article-22239.r53">[53]</xref><xref ref-type="bibr" rid="article-22239.r54">[54]</xref><xref ref-type="bibr" rid="article-22239.r55">[55]</xref>&#x000a0;The decision between intralesional curettage and wide resection is often made based on the tumor's location, size, aggressiveness, and the patient's overall health and preferences.</p>
        <p>Resection may be the preferred option&#x000a0;in benign tumors, particularly when bone salvageability&#x000a0;through intralesional methods would cause a severe compromise in mechanical characteristics.&#x000a0;This applies particularly to the&#x000a0;"expendable bones,"&#x000a0;such as the lower ulnar and upper fibular end, where excision may be the treatment of choice.</p>
        <p>In primary&#x000a0;and recurrent cases, especially when&#x000a0;the tumor involves the end of a long bone and causes significant dysfunction of the joint surface, reconstruction&#x000a0;becomes necessary. Several options are available for these cases, including mega prosthetic joint replacement, biologic reconstruction with an autograft, arthrodesis with internal/external fixation, microvascular fibula reconstruction, Ilizarov method of bone regeneration, and osteoarticular allograft.<xref ref-type="bibr" rid="article-22239.r1">[1]</xref><xref ref-type="bibr" rid="article-22239.r56">[56]</xref></p>
        <p>In the past, GCTs were&#x000a0;often&#x000a0;treated with amputations, wide resections, or reconstructions. However,&#x000a0;considering that&#x000a0;GCTs are benign yet locally aggressive tumors, a local intralesional surgical approach is deemed appropriate in most cases. Treatment options include curettage, curettage and bone grafting, curettage&#x000a0;with polymethylmethacrylate (PMMA) insertion, and primary resection. Radiation therapy and embolization of the feeding vessels are used for pelvic and sacral tumors that are not amenable to surgery.<xref ref-type="bibr" rid="article-22239.r57">[57]</xref></p>
        <p>Radiotherapy&#x000a0;is recommended for spinal, sacral, or aggressive tumors when complete excision or curettage is impractical for any functional or medical reasons. Intralesional curettage and bone grafting are&#x000a0;considered the&#x000a0;limb-sparing&#x000a0;treatment of choice, associated with&#x000a0;acceptable functional and oncologic outcomes. However, a simple curettage with or without a bone graft presents a 27% and 55% recurrence rate.&#x000a0;Many surgeons replace bone graft packing with PMMA packing due to&#x000a0;its high recurrence rate.</p>
        <p>Wide en-bloc resection is another option that offers the lowest recurrence rate and can be&#x000a0;used in expendable bones. For instance, wide resection without reconstruction is often performed in the proximal fibula. In cases of GCT in the distal radius, resection and reconstruction with an allograft or an autograft are commonly undertaken.</p>
        <p>
<bold>Adjuvant Treatments</bold>
</p>
        <p>Adjuvant treatments, such as liquid nitrogen, phenol, or HO&#x000a0;with argon beam coagulation,&#x000a0;demonstrate&#x000a0;excellent recurrence-free survival, especially when paired with intralesional curettage.&#x000a0;The effectiveness of treating&#x000a0;GCTs&#x000a0;hinges more on the aggressiveness of the intralesional curettage than on the specific adjuvant used. The tumor location, associated fractures, extensions to the soft tissue, and an understanding of the resection's functional consequences influence tumor removal's adequacy.</p>
        <p>Novel adjuvant therapies for GCTs include topical or systemic bisphosphonates like zoledronate or pamidronate. Bisphosphonates induce apoptosis and limit the tumor progression by targeting the osteoclast-like giant cells.<xref ref-type="bibr" rid="article-22239.r58">[58]</xref><xref ref-type="bibr" rid="article-22239.r59">[59]</xref>&#x000a0;A clinical trial comparing zoledronic acid and denosumab reported no significant difference in the clinical and radiological outcomes. However, there was a higher risk of local recurrence with denosumab,&#x000a0;though&#x000a0;not statistically significant.<xref ref-type="bibr" rid="article-22239.r23">[23]</xref>&#x000a0;Recently,&#x000a0;bisphosphonate&#x000a0;mixed bone cement has been reported as an adjuvant for GCT, as it directly targets neoplastic mononuclear stromal cells after curettage.<xref ref-type="bibr" rid="article-22239.r60">[60]</xref><xref ref-type="bibr" rid="article-22239.r61">[61]</xref></p>
        <p>Denosumab, a monoclonal antibody, is widely used to treat unresectable GCTs of bone in adults and skeletally-matured adolescents. It acts by specifically binding to RANKL. In addition to its primary use, denosumab has been utilized preoperatively&#x000a0;to&#x000a0;reduce the&#x000a0;tumor size,&#x000a0;diminish the tumor's blood supply, and&#x000a0;facilitate&#x000a0;joint preservation procedures in periarticular locations. However, consensus is lacking regarding the optimal dose and duration of denosumab&#x000a0;for adjuvant treatment or&#x000a0;in cases of inoperable tumors. Reports&#x000a0;suggest&#x000a0;increased chances of local recurrence and severe complications with long-term denosumab use, as it targets multinuclear giant cells without&#x000a0;affecting&#x000a0;neoplastic mononuclear stromal cells.<xref ref-type="bibr" rid="article-22239.r62">[62]</xref>&#x000a0;</p>
        <p>The Food and Drug Administration (FDA) has approved denosumab for use in&#x000a0;unresectable and metastatic GCT and in&#x000a0;cases where surgical management would harm the patient.<xref ref-type="bibr" rid="article-22239.r23">[23]</xref>&#x000a0;Initially, neoadjuvant denosumab use was described for 12 months. However,&#x000a0;due to&#x000a0;the risk of increased local recurrence&#x000a0;attributed to&#x000a0;denosumab's promotion of new bone formation, which&#x000a0;limits the identification of tumor margins, a short course of neoadjuvant denosumab has been studied. Comparative analyses indicate no&#x000a0;significant difference in clinical or radiological outcome and the histopathological response&#x000a0;between patients&#x000a0;receiving&#x000a0;a short course or long-term denosumab as a neoadjuvant therapy.<xref ref-type="bibr" rid="article-22239.r63">[63]</xref></p>
        <p>Sunitinib, a vascular endothelial growth factor receptor &#x003b2;-antagonist, has recently been reported for use with&#x000a0;denosumab. This combination therapy aims to decrease stromal cell viability.&#x000a0;Notably, its application was associated with completely eradicating giant and stromal cells in an adolescent patient with GCT.<xref ref-type="bibr" rid="article-22239.r64">[64]</xref></p>
        <p>Cyclolinopeptide, a novel molecule extracted from linseed,&#x000a0;has emerged as a potential&#x000a0;new drug&#x000a0;for GCTs. This compound possesses cytoprotective and immunosuppressive properties and demonstrates inhibitory effects on RANKL-signaling and osteoclastic differentiation.<xref ref-type="bibr" rid="article-22239.r65">[65]</xref>&#x000a0;Exploring cyclolinopeptide introduces a promising avenue for novel therapeutic interventions in GCT, offering an alternative approach to managing the disease. While further research and clinical studies are needed to assess the safety and efficacy of these newer novel agents, no recognized effective chemotherapeutic agent is currently available to manage GCTS.</p>
      </sec>
      <sec id="article-22239.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Based on the radiographic findings, the differential diagnoses for GCTs include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lytic metastatic lesion (particularly&#x000a0;a vascular metastasis from thyroid or renal cell carcinoma)</p>
          </list-item>
          <list-item>
            <p>Primary bone tumor</p>
          </list-item>
          <list-item>
            <p>Brown tumor of hyperparathyroidism</p>
          </list-item>
          <list-item>
            <p>Nonossifying fibroma</p>
          </list-item>
          <list-item>
            <p>Aneurysmal bone cyst</p>
          </list-item>
          <list-item>
            <p>Fibrous metaphyseal defects</p>
          </list-item>
          <list-item>
            <p>Osteoblastoma</p>
          </list-item>
          <list-item>
            <p>Chondroblastoma</p>
          </list-item>
          <list-item>
            <p>Malignant fibrous histiocytoma</p>
          </list-item>
          <list-item>
            <p>Telangiectatic osteosarcoma.<xref ref-type="bibr" rid="article-22239.r45">[45]</xref><xref ref-type="bibr" rid="article-22239.r66">[66]</xref></p>
          </list-item>
        </list>
        <p>Notably,&#x000a0;mutations within the&#x000a0;H3F3A&#x000a0;gene can distinguish GCT from other entities, as they are identified&#x000a0;in up to 96% of cases.<xref ref-type="bibr" rid="article-22239.r67">[67]</xref><xref ref-type="bibr" rid="article-22239.r68">[68]</xref>&#x000a0;However, a mutation in&#x000a0;H3F3A&#x000a0;does not entirely exclude malignancy in other osteoclast-rich tumors, like chondroblastoma, aneurysmal bone cyst, or nonossifying fibroma.<xref ref-type="bibr" rid="article-22239.r53">[53]</xref><xref ref-type="bibr" rid="article-22239.r55">[55]</xref>&#x000a0;Specifically, chondroblastomas have a high frequency of mutations in histone 3.3 genes.<xref ref-type="bibr" rid="article-22239.r69">[69]</xref></p>
      </sec>
      <sec id="article-22239.s11" sec-type="Staging">
        <title>Staging</title>
        <p>Various&#x000a0;classifications of GCTs have been&#x000a0;proposed based on histology&#x000a0;and clinical and radiographic appearance, although&#x000a0;their clinical utility can be limited.&#x000a0;The Campanacci grading system, however, provides a helpful framework:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Grade I:&#x000a0;</bold>Intraosseous lesions with well-marginated borders and an intact cortex.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Grade II:&#x000a0;</bold>More extensive intraosseous lesions associated with a thin cortex without loss of cortical continuity.
<list list-type="bullet"><list-item><p>IIA: Without pathological fracture.</p></list-item><list-item><p>IIB: With pathological fracture.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Grade III:</bold>&#x000a0;Extraosseous lesions that extend into soft tissue.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22239.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Recurrence occurring after&#x000a0;3 years has been considered exceptional in the literature,<xref ref-type="bibr" rid="article-22239.r51">[51]</xref>&#x000a0;with the local recurrence rate for GCTs&#x000a0;ranging&#x000a0;from 20% to 50%, averaging 33%.<xref ref-type="bibr" rid="article-22239.r41">[41]</xref><xref ref-type="bibr" rid="article-22239.r70">[70]</xref>&#x000a0;Modern curettage techniques&#x000a0;have&#x000a0;contributed to an improvement in the GCT local control rate.&#x000a0;Total serum acid phosphatase is&#x000a0;suggested as a tumor marker to monitor the response to GCT treatment.&#x000a0;While&#x000a0;an increase in tumor grade from I to III&#x000a0;may not necessarily reflect the biological aggressiveness of the tumor, there is an observed increase in the recurrence rate in grade III lesions. A true spontaneous transformation to malignancy has been reported in very few cases.<xref ref-type="bibr" rid="article-22239.r71">[71]</xref>&#x000a0;</p>
        <p>Pulmonary metastases&#x000a0;account for about 16% to 25% of relapsed GCT cases, although they are seen in only&#x000a0;1% to 6% of primary cases. Treatment for pulmonary metastases involves wide resection, often combined with interferon alfa, chemotherapy, and radiation.&#x000a0;In cases where complete surgical excision is not possible, adjuvant treatments,&#x000a0;like radiation or chemotherapy, are generally recommended. For unresectable metastases,&#x000a0;a combination&#x000a0;of chemotherapy and radiation therapy is implemented. Lung metastases can have poor outcomes.<xref ref-type="bibr" rid="article-22239.r72">[72]</xref><xref ref-type="bibr" rid="article-22239.r73">[73]</xref><xref ref-type="bibr" rid="article-22239.r74">[74]</xref>&#x000a0;</p>
        <p>Metastases&#x000a0;of bone GCT are&#x000a0;relatively rare, occurring in approximately 3% of cases, but the behavior of pulmonary metastasis is unpredictable.<xref ref-type="bibr" rid="article-22239.r75">[75]</xref><xref ref-type="bibr" rid="article-22239.r76">[76]</xref><xref ref-type="bibr" rid="article-22239.r77">[77]</xref>&#x000a0;Younger patients with local recurrence, Enneking stage-III disease, or axial&#x000a0;involvement are at an increased risk.<xref ref-type="bibr" rid="article-22239.r68">[68]</xref>&#x000a0;Histologically, metastatic lesions&#x000a0;resemble&#x000a0;primary lesions. The mean interval between the onset of the tumor and the detection of pulmonary metastasis is approximately 18 to 24 months.<xref ref-type="bibr" rid="article-22239.r68">[68]</xref>&#x000a0;Complete excision of the metastases has&#x000a0;shown success with good long-term survival,&#x000a0;although those with comorbidities may eventually&#x000a0;succumb&#x000a0;to the metastases.<xref ref-type="bibr" rid="article-22239.r1">[1]</xref></p>
        <p>In cases where a primary bone sarcoma is suspected within prominent areas of giant cell reaction and hemorrhage in a newly discovered GCT that was initially missed, it is essential to consider the possibility of malignancy rather than assuming a malignant transformation.<xref ref-type="bibr" rid="article-22239.r78">[78]</xref>&#x000a0;Malignant transformations in GCT can result in osteosarcoma, malignant histiocytoma, or fibrosarcoma. The occurrence of malignant transformation&#x000a0;may be identified several years after the initial surgery, with a range of&#x000a0;4 to 40 years from the initial surgery.<xref ref-type="bibr" rid="article-22239.r79">[79]</xref></p>
        <p>Overall, GCTs&#x000a0;have a favorable&#x000a0;prognosis. Pulmonary metastases can&#x000a0;contribute to death in 16% to 25%.&#x000a0;When a true malignant transformation occurs within a GCT, the prognosis is comparatively worse than that for a benign GCT. Nonetheless, it&#x000a0;tends to be&#x000a0;somewhat better than&#x000a0;the&#x000a0;prognosis for other high-grade sarcomas.</p>
      </sec>
      <sec id="article-22239.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Giant cell tumors of the bone can be complicated by the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tumor recurrence</p>
          </list-item>
          <list-item>
            <p>Osteoarthritis of the knee joint</p>
          </list-item>
          <list-item>
            <p>Stress fracture</p>
          </list-item>
          <list-item>
            <p>Limited movement</p>
          </list-item>
          <list-item>
            <p>Pulmonary metastasis</p>
          </list-item>
          <list-item>
            <p>Local and deep infections</p>
          </list-item>
          <list-item>
            <p>Osteomyelitis</p>
          </list-item>
          <list-item>
            <p>Joint degeneration</p>
          </list-item>
          <list-item>
            <p>Hardware failure</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22239.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>As the exact cause of GCTs, like most other tumors, remains unclear, preventive measures for their occurrence are unknown. However, educating patients about the potential presentations of local invasion or metastasis is crucial, enabling them to seek medical advice early in the process. Early detection often leads to better outcomes. Additionally, educating patients about surgical treatment options is of utmost importance, empowering them to make informed decisions that can significantly impact the overall outcomes. Patient awareness and involvement are vital in managing GCT and optimizing the treatment journey.</p>
      </sec>
      <sec id="article-22239.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>A few key facts to remember about GCT include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bone GCT is a benign but locally aggressive primary bone tumor.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mutation in the H3F3A gene&#x000a0;is a&#x000a0;specific marker for diagnosing GCT.<xref ref-type="bibr" rid="article-22239.r80">[80]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Local control involves tumor removal with curettage therapies chosen for acceptable long-term&#x000a0;outcomes&#x000a0;and functional consequences.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Post-treatment monitoring includes serial chest and site radiographs and serial physical examinations.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Relapses may manifest as new swelling or pain.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tumor recurrence can occur many years after initial involvement and treatment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Recommended practice includes at&#x000a0;least a 5-year close follow-up.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intensified surveillance, preferably with CT,&#x000a0;is advised for pulmonary metastasis detection in&#x000a0;patients with a local recurrence of bone GCT,&#x000a0;particularly&#x000a0;in&#x000a0;the first&#x000a0;3 years&#x000a0;after diagnosis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22239.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients diagnosed with GCT benefit significantly from a collaborative and inter-professional healthcare team. In the initial stages, primary care providers or emergency physicians are often patients' first point of contact. Chiropractors may also be crucial in identifying GCT through radiographs and should promptly refer patients to the appropriate specialist. After&#x000a0;identifying bone tumors on plain x-rays, orthopedic surgeons become pivotal in further evaluation and management. Radiologists provide interpretations of imaging studies to aid in the diagnostic process. The specialized care of orthopedic oncologists becomes essential for appropriate surgical interventions. Nursing professionals are integral throughout the care continuum, assisting in preoperative, surgical, and postoperative care. Additionally, rehabilitation specialists, such as occupational or physical therapists, contribute significantly to the patient's recovery, facilitating a prompt return to their daily activities. This collaborative approach ensures optimal care and aims to achieve the best possible outcomes for patients dealing with GCT.</p>
      </sec>
      <sec id="article-22239.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22239&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22239">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/giant-cell-tumor-osteoclastoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22239">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22239/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22239">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22239.s18">
        <fig id="article-22239.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Lytic Lesion. The radiograph of the right knee, featuring anteroposterior and lateral views, reveals a lytic lesion in the medial condyle of the right proximal tibia. These findings are indicative of a potential giant cell tumor. Contributed by VT</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="GCT__Preop" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22239.s19">
        <title>References</title>
        <ref id="article-22239.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sobti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Agarwala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Giant Cell Tumor of Bone - An Overview.</article-title>
            <source>Arch Bone Jt Surg</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-9</page-range>
            <pub-id pub-id-type="pmid">26894211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghostine</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sebaaly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghanem</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Multifocal metachronous giant cell tumor: case report and review of the literature.</article-title>
            <source>Case Rep Med</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>678035</fpage>
            <pub-id pub-id-type="pmid">24511316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Werner</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumour of bone: morphological, biological and histogenetical aspects.</article-title>
            <source>Int Orthop</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>484</fpage>
            <page-range>484-9</page-range>
            <pub-id pub-id-type="pmid">17013643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCarthy</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Shibui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miyaoka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sobue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Palis</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Dolecek</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kruchko</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Engelhard</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Villano</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries.</article-title>
            <source>Neuro Oncol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>9</issue>
            <fpage>1194</fpage>
            <page-range>1194-200</page-range>
            <pub-id pub-id-type="pmid">22869621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>A clinical overview of centrosome amplification in human cancers.</article-title>
            <source>Int J Biol Sci</source>
            <year>2011</year>
            <volume>7</volume>
            <issue>8</issue>
            <fpage>1122</fpage>
            <page-range>1122-44</page-range>
            <pub-id pub-id-type="pmid">22043171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Juliao</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Sciadini</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Telomerase activity and oncogenesis in giant cell tumor of bone.</article-title>
            <source>Cancer</source>
            <year>1995</year>
            <month>Mar</month>
            <day>01</day>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>1094</fpage>
            <page-range>1094-9</page-range>
            <pub-id pub-id-type="pmid">7850706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mavrogenis</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Igoumenou</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Megaloikonomos</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Panagopoulos</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Papagelopoulos</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Soucacos</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone revisited.</article-title>
            <source>SICOT J</source>
            <year>2017</year>
            <volume>3</volume>
            <fpage>54</fpage>
            <pub-id pub-id-type="pmid">28905737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donthineni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boriani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ofluoglu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bandiera</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Metastatic behaviour of giant cell tumour of the spine.</article-title>
            <source>Int Orthop</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>497</fpage>
            <page-range>497-501</page-range>
            <pub-id pub-id-type="pmid">18461324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viswanathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jambhekar</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities?</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>468</volume>
            <issue>3</issue>
            <fpage>827</fpage>
            <page-range>827-33</page-range>
            <pub-id pub-id-type="pmid">19597900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Umer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment and recurrence of giant cell tumors of bone - A retrospective cohort from a developing country.</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>48</volume>
            <fpage>29</fpage>
            <page-range>29-34</page-range>
            <pub-id pub-id-type="pmid">31687136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Unusual Presentation of Giant Cell Tumor in Skeletally Immature Patient in Diaphysis of Ulna.</article-title>
            <source>J Orthop Case Rep</source>
            <year>2015</year>
            <season>Apr-Jun</season>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>28</fpage>
            <page-range>28-31</page-range>
            <pub-id pub-id-type="pmid">27299037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shekhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murgod</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Korlhalli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Synchronous Multicentric Giant Cell Tumour (GCT)-A Rare Case Report.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>185</fpage>
            <page-range>185-6</page-range>
            <pub-id pub-id-type="pmid">24701530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verma</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Puri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rekhi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gulia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Giant Cell Tumor Developing in Paget's Disease of Bone: A Case Report with Review of Literature.</article-title>
            <source>J Orthop Case Rep</source>
            <year>2016</year>
            <season>Sep-Oct</season>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>103</fpage>
            <page-range>103-107</page-range>
            <pub-id pub-id-type="pmid">28164066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dufresne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Derbel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cassier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vaz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Decouvelaere</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Giant-cell tumor of bone, anti-RANKL therapy.</article-title>
            <source>Bonekey Rep</source>
            <year>2012</year>
            <month>Sep</month>
            <day>05</day>
            <volume>1</volume>
            <fpage>149</fpage>
            <pub-id pub-id-type="pmid">24363925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Trivett</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kansara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schlicht</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dickinson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Choong</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Holloway</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB.</article-title>
            <source>Am J Pathol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>167</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-28</page-range>
            <pub-id pub-id-type="pmid">15972958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukaihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suehara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kohsaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akaike</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kazuno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okubo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>e0148401</fpage>
            <pub-id pub-id-type="pmid">26863138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyce</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Functions of RANKL/RANK/OPG in bone modeling and remodeling.</article-title>
            <source>Arch Biochem Biophys</source>
            <year>2008</year>
            <month>May</month>
            <day>15</day>
            <volume>473</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-46</page-range>
            <pub-id pub-id-type="pmid">18395508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindeman</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hanemaaijer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dijkstra</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Szuhai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bromme</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verheijen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Cathepsin K is the principal protease in giant cell tumor of bone.</article-title>
            <source>Am J Pathol</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>165</volume>
            <issue>2</issue>
            <fpage>593</fpage>
            <page-range>593-600</page-range>
            <pub-id pub-id-type="pmid">15277232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behjati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tarpey</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Presneau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scheipl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pillay</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Van Loo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wedge</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gundem</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nik-Zainal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McLaren</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goodie</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teague</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Halai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Myklebost</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Baumhoer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jundt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hamoudi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tirabosco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amary</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Futreal</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Stratton</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.</article-title>
            <source>Nat Genet</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>12</issue>
            <fpage>1479</fpage>
            <page-range>1479-82</page-range>
            <pub-id pub-id-type="pmid">24162739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steensma</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tyler</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Shaber</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Goldring</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Healey</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Purdue</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>e69101</fpage>
            <pub-id pub-id-type="pmid">23922683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kushlinskii</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Alferov</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Timofeev</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Gershtein</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Bulycheva</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Bondarev</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Shchupak</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Sokolov</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Polikarpova</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Efimova</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Dzampaev</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sushentsov</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Aliev</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Musaev</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors.</article-title>
            <source>Bull Exp Biol Med</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>170</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-68</page-range>
            <pub-id pub-id-type="pmid">33231796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Annaratone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Linari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Osella-Abate</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Musuraca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Veneziano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vignale</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertero</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cassoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ratto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Comandone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grignani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Piana</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Papotti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone.</article-title>
            <source>Cancer Immunol Immunother</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>69</volume>
            <issue>9</issue>
            <fpage>1905</fpage>
            <page-range>1905-1916</page-range>
            <pub-id pub-id-type="pmid">32377818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Heijden</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lipplaa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Langevelde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bov&#x000e9;e</surname>
                <given-names>JVMG</given-names>
              </name>
              <name>
                <surname>van de Sande</surname>
                <given-names>MAJ</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Updated concepts in treatment of giant cell tumor of bone.</article-title>
            <source>Curr Opin Oncol</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>371</fpage>
            <page-range>371-378</page-range>
            <pub-id pub-id-type="pmid">35837707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kundu</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dhiman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Siwach</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rana</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effect of Intravenous Zoledronic Acid on Histopathology and Recurrence after Extended Curettage in Giant Cell Tumors of Bone: A Comparative Prospective Study.</article-title>
            <source>Indian J Orthop</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-50</page-range>
            <pub-id pub-id-type="pmid">29416169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Purohit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pardiwala</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Imaging of giant cell tumor of bone.</article-title>
            <source>Indian J Orthop</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-6</page-range>
            <pub-id pub-id-type="pmid">21139758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>ALCAM<sup>+</sup> stromal cells: role in giant cell tumor of bone progression.</article-title>
            <source>Cell Death Dis</source>
            <year>2018</year>
            <month>Feb</month>
            <day>20</day>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <pub-id pub-id-type="pmid">29463803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salerno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Avnet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alberghini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giunti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Histogenetic characterization of giant cell tumor of bone.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>466</volume>
            <issue>9</issue>
            <fpage>2081</fpage>
            <page-range>2081-91</page-range>
            <pub-id pub-id-type="pmid">18543051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akeho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yumoto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor bone. Enzyme histochemical, biochemical and tissue culture studies.</article-title>
            <source>Virchows Arch A Pathol Anat Histol</source>
            <year>1982</year>
            <volume>395</volume>
            <issue>3</issue>
            <fpage>319</fpage>
            <page-range>319-30</page-range>
            <pub-id pub-id-type="pmid">6287714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turcotte</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone.</article-title>
            <source>Orthop Clin North Am</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-51</page-range>
            <pub-id pub-id-type="pmid">16311110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Dahir</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Telomere reduction in giant cell tumor of bone and with aging.</article-title>
            <source>Cancer Genet Cytogenet</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>71</volume>
            <issue>2</issue>
            <fpage>132</fpage>
            <page-range>132-8</page-range>
            <pub-id pub-id-type="pmid">8281516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.</article-title>
            <source>Tumour Biol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>495</fpage>
            <page-range>495-501</page-range>
            <pub-id pub-id-type="pmid">25618600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xiu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone with H3F3B mutation: A case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2023</year>
            <month>Feb</month>
            <day>17</day>
            <volume>102</volume>
            <issue>7</issue>
            <fpage>e32995</fpage>
            <pub-id pub-id-type="pmid">36800629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yakoub</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Torrence</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bartelstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Healey</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hameed</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Giant-cell-poor giant cell tumor of bone: report of two cases and literature review.</article-title>
            <source>Skeletal Radiol</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>1791</fpage>
            <page-range>1791-1798</page-range>
            <pub-id pub-id-type="pmid">36781420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Lorentzon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boquist</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish Cancer Registry for the years 1958 through 1968.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>1975</year>
            <month>Mar</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-73</page-range>
            <pub-id pub-id-type="pmid">1112843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeys</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Suneja</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chami</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grimer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Tillman</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Impending fractures in giant cell tumours of the distal femur: incidence and outcome.</article-title>
            <source>Int Orthop</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-8</page-range>
            <pub-id pub-id-type="pmid">16474936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>VO</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mendoza</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Primus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peabody</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Argon beam coagulation as an adjuvant for local control of giant cell tumor.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>454</volume>
            <fpage>192</fpage>
            <page-range>192-7</page-range>
            <pub-id pub-id-type="pmid">16957652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoeffel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Galloy</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Grignon</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chastagner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Floquet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mainard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kadiri</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone in children and adolescents.</article-title>
            <source>Rev Rhum Engl Ed</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>63</volume>
            <issue>9</issue>
            <fpage>618</fpage>
            <page-range>618-23</page-range>
            <pub-id pub-id-type="pmid">8938873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shih</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Excision curettage and allografting of giant cell tumor.</article-title>
            <source>World J Surg</source>
            <year>1998</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>432</fpage>
            <page-range>432-7</page-range>
            <pub-id pub-id-type="pmid">9564283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bridge</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Neff</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mouron</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone. Chromosomal analysis of 48 specimens and review of the literature.</article-title>
            <source>Cancer Genet Cytogenet</source>
            <year>1992</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-13</page-range>
            <pub-id pub-id-type="pmid">1728946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Toriyama</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment of giant cell tumors of the pelvis.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>1987</year>
            <month>Sep</month>
            <issue>222</issue>
            <fpage>123</fpage>
            <page-range>123-31</page-range>
            <pub-id pub-id-type="pmid">3621712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eckardt</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>1986</year>
            <month>Mar</month>
            <issue>204</issue>
            <fpage>45</fpage>
            <page-range>45-58</page-range>
            <pub-id pub-id-type="pmid">3514036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tornberg</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Multicentric giant-cell tumors in the long bones. A case report.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>1975</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>420</fpage>
            <page-range>420-2</page-range>
            <pub-id pub-id-type="pmid">1123400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayashida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawabata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Takeyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inaba</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of Patients with Giant Cell Tumor of Bone and High Serum Tartrate-Resistant Acid Phosphatase 5b Levels: Comparison of Tumor Volume and Clinical Factors.</article-title>
            <source>J Nippon Med Sch</source>
            <year>2022</year>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>572</fpage>
            <page-range>572-579</page-range>
            <pub-id pub-id-type="pmid">36725001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Marchiori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Severo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Magnetic resonance imaging aspects of giant-cell tumours of bone.</article-title>
            <source>J Med Imaging Radiat Oncol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>58</volume>
            <issue>6</issue>
            <fpage>674</fpage>
            <page-range>674-8</page-range>
            <pub-id pub-id-type="pmid">25256094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavanna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Biasini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Monfredo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maniscalco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone.</article-title>
            <source>Oncologist</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>1207</fpage>
            <pub-id pub-id-type="pmid">25378541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cleven</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>H&#x000f6;cker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Briaire-de Bruijn</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Szuhai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cleton-Jansen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bov&#x000e9;e</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>11</issue>
            <fpage>1576</fpage>
            <page-range>1576-83</page-range>
            <pub-id pub-id-type="pmid">26457357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fellenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>S&#x000e4;hr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mancarella</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Plass</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lindroth</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Westhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lehner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ewerbeck</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells.</article-title>
            <source>Cancer Lett</source>
            <year>2019</year>
            <month>Apr</month>
            <day>28</day>
            <volume>448</volume>
            <fpage>61</fpage>
            <page-range>61-69</page-range>
            <pub-id pub-id-type="pmid">30742944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dreinh&#x000f6;fer</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Rydholm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kreicbergs</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Giant-cell tumours with fracture at diagnosis. Curettage and acrylic cementing in ten cases.</article-title>
            <source>J Bone Joint Surg Br</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>189</fpage>
            <page-range>189-93</page-range>
            <pub-id pub-id-type="pmid">7706330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rock</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Curettage of giant cell tumor of bone. Factors influencing local recurrences and metastasis.</article-title>
            <source>Chir Organi Mov</source>
            <year>1990</year>
            <volume>75</volume>
            <issue>1 Suppl</issue>
            <fpage>204</fpage>
            <page-range>204-5</page-range>
            <pub-id pub-id-type="pmid">2249533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bettelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Capanna</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Curettage of giant cell tumor of bone. Introduction--material and methods.</article-title>
            <source>Chir Organi Mov</source>
            <year>1990</year>
            <volume>75</volume>
            <issue>1 Suppl</issue>
            <fpage>203</fpage>
            <pub-id pub-id-type="pmid">2249532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lausten</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Schi&#x000f8;dt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Local recurrences in giant cell tumour of bone. Long-term follow up of 31 cases.</article-title>
            <source>Int Orthop</source>
            <year>1996</year>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>172</fpage>
            <page-range>172-6</page-range>
            <pub-id pub-id-type="pmid">8832321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campanacci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boriani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sudanese</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Giant-cell tumor of bone.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>1987</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>106</fpage>
            <page-range>106-14</page-range>
            <pub-id pub-id-type="pmid">3805057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sung</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>1982</year>
            <month>Jun</month>
            <volume>64</volume>
            <issue>5</issue>
            <fpage>755</fpage>
            <page-range>755-61</page-range>
            <pub-id pub-id-type="pmid">7045129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Dahlin</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Giant-cell tumor of bone.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>1986</year>
            <month>Feb</month>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>235</fpage>
            <page-range>235-42</page-range>
            <pub-id pub-id-type="pmid">3511063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsuneyoshi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwamoto</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone: oncological and functional results of long-term follow-up.</article-title>
            <source>Jpn J Clin Oncol</source>
            <year>1998</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>323</fpage>
            <page-range>323-8</page-range>
            <pub-id pub-id-type="pmid">9703860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Heijden</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dijkstra</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>van de Sande</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kroep</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Nout</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>van Rijswijk</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Bov&#x000e9;e</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The clinical approach toward giant cell tumor of bone.</article-title>
            <source>Oncologist</source>
            <year>2014</year>
            <month>May</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>550</fpage>
            <page-range>550-61</page-range>
            <pub-id pub-id-type="pmid">24718514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment of giant cell tumor of bone: Current concepts.</article-title>
            <source>Indian J Orthop</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-8</page-range>
            <pub-id pub-id-type="pmid">21139760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujimoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Seichi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terahara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tago</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hosoi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohtomo</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A new bisphosphonate treatment option for giant cell tumors.</article-title>
            <source>Oncol Rep</source>
            <year>2001</year>
            <season>May-Jun</season>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>643</fpage>
            <page-range>643-7</page-range>
            <pub-id pub-id-type="pmid">11295095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Suratwala</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Doppelt</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>Blaine</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Winchester</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>FY</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2004</year>
            <month>Sep</month>
            <issue>426</issue>
            <fpage>103</fpage>
            <page-range>103-9</page-range>
            <pub-id pub-id-type="pmid">15346059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zwolak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Manivel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Jasinski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kirstein</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Dudek</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>EY</given-names>
              </name>
            </person-group>
            <article-title>Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>92</volume>
            <issue>1</issue>
            <fpage>162</fpage>
            <page-range>162-8</page-range>
            <pub-id pub-id-type="pmid">20048108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenberg</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>FY</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Tumor of Bone: A 1 to 12-Year Follow-up Study.</article-title>
            <source>Am J Clin Oncol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-237</page-range>
            <pub-id pub-id-type="pmid">30811352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Nov</month>
            <day>23</day>
            <volume>14</volume>
            <issue>23</issue>
            <pub-id pub-id-type="pmid">36497239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hindiskere</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Errani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Doddarangappa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramaswamy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chinder</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>478</volume>
            <issue>11</issue>
            <fpage>2522</fpage>
            <page-range>2522-2533</page-range>
            <pub-id pub-id-type="pmid">32401001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahdal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neradil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mudry</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Paukovcekova</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Staniczkova Zambo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Macsek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pazourek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tomas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Veselska</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFR&#x003b2; Signaling.</article-title>
            <source>Cancers (Basel)</source>
            <year>2021</year>
            <month>Jul</month>
            <day>15</day>
            <volume>13</volume>
            <issue>14</issue>
            <pub-id pub-id-type="pmid">34298757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taniguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miwa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Higuchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yonezawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morinaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kamei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nugroho</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Kaneda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsuchiya</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Anti-tumor Effects of Cyclolinopeptide on Giant-cell Tumor of the Bone.</article-title>
            <source>Anticancer Res</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>11</issue>
            <fpage>6145</fpage>
            <page-range>6145-6153</page-range>
            <pub-id pub-id-type="pmid">31704842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakarun</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Forrester</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Gottsegen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Matcuk</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone: review, mimics, and new developments in treatment.</article-title>
            <source>Radiographics</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>197</fpage>
            <page-range>197-211</page-range>
            <pub-id pub-id-type="pmid">23322837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siebenrock</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Unni</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Rock</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up.</article-title>
            <source>J Bone Joint Surg Br</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-7</page-range>
            <pub-id pub-id-type="pmid">9460951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Reith</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for pulmonary metastases from giant cell tumor of bone.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>2015</year>
            <month>Mar</month>
            <day>04</day>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>420</fpage>
            <page-range>420-8</page-range>
            <pub-id pub-id-type="pmid">25740033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Domovitov</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Healey</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Primary malignant giant-cell tumor of bone has high survival rate.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>694</fpage>
            <page-range>694-701</page-range>
            <pub-id pub-id-type="pmid">19902306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldenberg</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Bonfiglio</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Giant-cell tumor of bone. An analysis of two hundred and eighteen cases.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>1970</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>619</fpage>
            <page-range>619-64</page-range>
            <pub-id pub-id-type="pmid">5479455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aoki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shinozaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takagishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishijima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.</article-title>
            <source>Radiology</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>219</volume>
            <issue>3</issue>
            <fpage>774</fpage>
            <page-range>774-7</page-range>
            <pub-id pub-id-type="pmid">11376267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>W&#x000fc;lling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Engels</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jesse</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Delling</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The nature of giant cell tumor of bone.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>127</volume>
            <issue>8</issue>
            <fpage>467</fpage>
            <page-range>467-74</page-range>
            <pub-id pub-id-type="pmid">11501745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schremper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gebert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ahrens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Streitbuerger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koehler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hardes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gosheger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone: treatment and outcome of 214 cases.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>134</volume>
            <issue>9</issue>
            <fpage>969</fpage>
            <page-range>969-78</page-range>
            <pub-id pub-id-type="pmid">18322700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahrens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Streitbuerger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koehler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Winkelmann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gosheger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hardes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment options for recurrent giant cell tumors of bone.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>135</volume>
            <issue>1</issue>
            <fpage>149</fpage>
            <page-range>149-58</page-range>
            <pub-id pub-id-type="pmid">18521629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vult von Steyern</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Trovik</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kivioja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bergh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Holmberg J&#x000f6;rgensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Foller&#x000e5;s</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rydholm</surname>
                <given-names>A</given-names>
              </name>
              <collab>Scandinavian Sarcoma Group</collab>
            </person-group>
            <article-title>Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing. A Scandinavian Sarcoma Group study.</article-title>
            <source>J Bone Joint Surg Br</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>531</fpage>
            <page-range>531-5</page-range>
            <pub-id pub-id-type="pmid">16567792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feigenberg</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Zlotecki</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Scarborough</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Enneking</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Whole-lung radiotherapy for giant cell tumors of bone with pulmonary metastases.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2002</year>
            <month>Aug</month>
            <issue>401</issue>
            <fpage>202</fpage>
            <page-range>202-8</page-range>
            <pub-id pub-id-type="pmid">12151897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Present</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Enneking</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Giant-cell tumor of bone with pulmonary metastases.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>1985</year>
            <month>Jul</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>890</fpage>
            <page-range>890-900</page-range>
            <pub-id pub-id-type="pmid">4019539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enneking</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Spanier</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>A system for the surgical staging of musculoskeletal sarcoma.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>1980</year>
            <season>Nov-Dec</season>
            <issue>153</issue>
            <fpage>106</fpage>
            <page-range>106-20</page-range>
            <pub-id pub-id-type="pmid">7449206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmerini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Picci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reichardt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Downey</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Malignancy in Giant Cell Tumor of Bone: A Review of the Literature.</article-title>
            <source>Technol Cancer Res Treat</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>18</volume>
            <fpage>1533033819840000</fpage>
            <pub-id pub-id-type="pmid">30935298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22239.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rekhi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Giant cell tumor of bone: An update, including spectrum of pathological features, pathogenesis, molecular profile and the differential diagnoses.</article-title>
            <source>Histol Histopathol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-153</page-range>
            <pub-id pub-id-type="pmid">35766228</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
